Literature DB >> 20444564

Targeting the TGR5-GLP-1 pathway to combat type 2 diabetes and non-alcoholic fatty liver disease.

T W H Pols1, J Auwerx, K Schoonjans.   

Abstract

Incretin-based therapies have shown promise in the treatment of type 2 diabetes. Here we review our current understanding of TGR5 as a target to induce glucagon-like peptide-1 (GLP-1) secretion. These new observations suggest that TGR5 agonists may constitute a novel approach to treat type 2 diabetes, as well as complications of diabetes, such as non-alcoholic fatty liver disease. Copyright 2010 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20444564     DOI： 10.1016/j.gcb.2010.03.009

Source DB:  PubMed          Journal:  Gastroenterol Clin Biol        ISSN： 0399-8320


  3 in total

1.  Probing the Binding Site of Bile Acids in TGR5.

Authors:  Antonio Macchiarulo; Antimo Gioiello; Charles Thomas; Thijs W H Pols; Roberto Nuti; Cristina Ferrari; Nicola Giacchè; Francesca De Franco; Mark Pruzanski; Johan Auwerx; Kristina Schoonjans; Roberto Pellicciari
Journal:  ACS Med Chem Lett       Date:  2013-10-15       Impact factor: 4.345

2.  Integrated Datasets of Proteomic and Metabolomic Biomarkers to Predict Its Impacts on Comorbidities of Type 2 Diabetes Mellitus.

Authors:  Amrita K Cheema; Prabhjit Kaur; Amina Fadel; Noura Younes; Mahmoud Zirie; Nasser M Rizk
Journal:  Diabetes Metab Syndr Obes       Date:  2020-07-07       Impact factor: 3.168

Review 3.  Bile Acid Receptors and the Gut-Liver Axis in Nonalcoholic Fatty Liver Disease.

Authors:  Rui Xue; Lianyong Su; Shengyi Lai; Yanyan Wang; Derrick Zhao; Jiangao Fan; Weidong Chen; Phillip B Hylemon; Huiping Zhou
Journal:  Cells       Date:  2021-10-20       Impact factor: 7.666
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.